CN102462699A - Use of porcine lung extract as matrix metalloproteinase inhibitor - Google Patents
Use of porcine lung extract as matrix metalloproteinase inhibitor Download PDFInfo
- Publication number
- CN102462699A CN102462699A CN2011101892182A CN201110189218A CN102462699A CN 102462699 A CN102462699 A CN 102462699A CN 2011101892182 A CN2011101892182 A CN 2011101892182A CN 201110189218 A CN201110189218 A CN 201110189218A CN 102462699 A CN102462699 A CN 102462699A
- Authority
- CN
- China
- Prior art keywords
- mmp
- purposes
- sus domestica
- pulmonis sus
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 210000004072 lung Anatomy 0.000 title abstract 3
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims abstract description 28
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims abstract description 28
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 27
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 27
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims abstract description 22
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims abstract description 22
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 20
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 20
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 108010004032 Bromelains Proteins 0.000 claims description 3
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims description 3
- 102100034866 Kallikrein-6 Human genes 0.000 claims description 3
- 238000003916 acid precipitation Methods 0.000 claims description 3
- 235000019835 bromelain Nutrition 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 claims description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 claims description 2
- 229940005991 chloric acid Drugs 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 239000000975 dye Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- -1 methoxyl group Chemical group 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010088090 pro-matrix metalloproteinase 9 Proteins 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- NCIAZCLIFWUDPR-UHFFFAOYSA-N 2-butyl-3,4,5,6-tetramethylphenol Chemical compound CCCCC1=C(C)C(C)=C(C)C(C)=C1O NCIAZCLIFWUDPR-UHFFFAOYSA-N 0.000 description 1
- 102000036664 ADAM10 Human genes 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 108090000560 Matrix metalloproteinase-15 Proteins 0.000 description 1
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
- 108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 1
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
- 108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 1
- 241000276489 Merlangius merlangus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- VIKVSUVYUVJHOA-UHFFFAOYSA-N octyl 3-phenylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C=CC1=CC=CC=C1 VIKVSUVYUVJHOA-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Abstract
The invention relates to a new application of pig lung extract as Matrix Metalloproteinase (MMP) inhibitor, in particular to the application of pig lung extract in inhibiting MMP-1, MMP-2 or/and MMP-9.
Description
Technical field
The present invention is relevant to the Pulmonis Sus domestica extract, and (Matrix Metalloproteinase, MMP) the new purposes of inhibitor is especially for suppressing MMP-1, MMP-2 or MMP-9 as matrix metalloproteinase.
Background technology
Metalloproteases is the ultra group of protease (ferment), and its number is in increasing sharp in recent years.Based on structure and functional consideration, these enzymes have been classified into several groups and subtribe crowd.The instance of metalloproteases comprises matrix metalloproteinase (MMP), such as collagenase (MMP-1; MMP-8, MMP-13), gelatinase (MMP-2, MMP-9), stromelysin (MMP-3; MMP10, MMP-11), a matter lysin (MMP-7), metalloelastase (MMP-12), enamel lysin (MMP-19), MT-MMP (MMP-14, MMP-15; MMP-16, MMP-17); Reproduction lysin or enamel lysin or MDC group, it comprises secretase and flows out enzyme, such as TNF invertase (ADAM10 and TACE): 3,4,3',4'-tetraketo-.beta.-carotene group, it comprises some enzymes, such as procollagen is handled protease (PCP); And other metalloproteases, for example assemble protoenzyme, endothelin-converting enzyme group and angiotonin invertase group.Wherein known MMP and multiple disease association; Like MMP when cancerous tissue medium vessels new life or the cancerometastasis; Its expression can raise or ferment can produce activation; In addition, the decomposition for extracellular matrix in the various diseases such as ulcer, beaevais' disease, osteoporosis, periodontal disease also has effect.Moreover; Active hyperfunction MMP will keep the phenomenon that important component is decomposed on the dermal composition to skin because of outside stimuluss such as ultraviolet make; Recently, because of its for since the activatory aging promotion factor of ultraviolet come into one's own especially, come into one's own especially with MMP-1, MMP-2 and MMP-9 especially; Its reason has two; The substrate of these MMP of the first is the important structure composition of skin, and two to be skin long term exposure stimulate these MMP to form under the factor of pathological states for example inflammatory reaction, oxidative stress and ultraviolet in meeting for it.Therefore, think that at present selectivity suppresses MMP-1, MMP-2 and MMP-9 and slowing down more helpful reaching effectively on the skin aging than suppressing all metalloproteases.
MMP-1 is collagen protein catabolic enzyme a kind of of common name; For regulating the photoaging important factor; Fibroblast is tanned by the sun by the ultraviolet of sunlight can cause the matrix metalloproteinase great expression, and then degradation of cell epimatrix (ECM), that is to say that MMP-1 is responsible for the collagen protein degraded of dermal tissue.
The importance that acts on the skin physiology of MMP-2 (dispergation ferment 72-kDa) also is confirmed.Though whether MMP-2 plays the part of direct role in the decomposition of type i collagen do not confirm as yet; But type i collagen be its zymolite obtained first confirm; In addition; IV Collagen Type VI (basement membrane), VII Collagen Type VI (corium-epidermis is decided the anchor microfibre), gelatin (rotten type i collagen), elastin laminin and fibrin etc. also all are the zymolites of MMP-2.Along with day at age is long, the ferment activity of MMP-2 in skin can increase, and therefore, MMP-2 also plays the part of important role aspect the atrophy of extracellular matrix.
MMP-9 (gelatinase B; 92kDa type I V collagenase; The 92kDa gelatinase) be a kind of excretory protein, it is at first purified in 1989, then asexual propagation and sequencing.Being expressed under the normal condition of MMP-9 is to be restricted to few cell types, comprises growing germinal layer, osteoclast, neutrophils and macrophage.But its expression can reach in other cell type in these same cells, and several amboceptors of mat bring out, and comprise that these cells are exposed to somatomedin or CYTOKINES.It is for often responding related identical amboceptor with the initiation inflammatory.The same through excretory MMP with other, MMP-9 disengages with not active proenzyme, and it is to divide subsequently and form the enzyme of tool enzyme activity.In in vivo supplying the needed protease of this activation, be to be the unknown.Active MMP9 is to the balance of organized enzyme not, is further in vivo via regulating with the reciprocal action of a kind of protein TIMP-1 (tissue depressant of metalloproteases-1) of natural generation.TIMP-1 is the C-stub area that is bonded to MMP-9, causes the inhibition at MMP-9 catalysis position.ProMMP-9 is through bringing out the balance of expression, and ProMMP-9 splits into active MMP9, and the existence of TIMP-1, is to merge the amount that is present in the tool catalytic activity MMP-9 of local location with decision.The MMP-9 of tool protein decomposing activity can attack and receive matter, and it comprises gelatin, elastin laminin and natural type I V and type V collagen; It does not have activity for natural type I collagen, proteoglycan or Thallus Laminariae (Thallus Eckloniae) amino acid.Data body in existing the growth, relevant with the role of MMP-9 in different physiologys and pathological process.Physiology role is included in the commitment of embryo transfer, and the embryo is grown the intrusion of germinal layer through uterine epithelium; Bone growth and developing certain role; And inflammatory cell is from the vascularity creep is extremely organized.Using the metric MMP-9 of EIA enzyme immunoassay to disengage, in fluid, and in the AM supernatant from untreated asthma patient, and from other groups of individuals person relatively, is to show the raising that lands.The MMP-9 that increases expresses and also has been found in some other pathology symptom; So make MMP-9 produce related with lysis; For example COPD, arthritis, neoplasm metastasis, Ah ear are grown extra large Mo's disease, multiple sclerosis; The speckle that reaches in the sclerosis of tremulous pulse atheroma breaks, and causes the acute coronary symptom, such as myocardial infarction.
Because the safety of natural product is good, is more and more paid attention to for the exploitation of natural origin product now, still have the natural product that needs exploitation to suppress MMP.
Summary of the invention
An object of the present invention is to provide a kind of purposes of Pulmonis Sus domestica extract, it is to be used for preparation to suppress the active compositions of matrix metalloproteinase (MMP).
The present invention describes in detail in the lower part.Further feature of the present invention, purpose and advantage can be prone to be shown in embodiment of the present invention and claims.
Description of drawings
Figure 1A is the toxicity test chart of Pulmonis Sus domestica extract to fibroblast; Figure 1B and C are that the Pulmonis Sus domestica extract of various concentration suppresses active colloid electrophoresis figure of MMP-1 and chart.
Fig. 2 A is the toxicity test chart of Pulmonis Sus domestica extract to fibroblast; Fig. 2 B and C are that the Pulmonis Sus domestica extract of various concentration suppresses MMP-2 and active colloid electrophoresis figure of MMP-9 and chart.Fig. 2 D is Pulmonis Sus domestica extract and the matched group of the variable concentrations suppression ratio for MMP-9.
The specific embodiment
Before of the present invention, do not have any report or prior art and point out or infer that the Pulmonis Sus domestica extract has the effect that suppresses matrix metalloproteinase, and in the present invention, find that unexpectedly the Pulmonis Sus domestica extract can effectively suppress matrix metal proteinase activity.Suppress active by this, particularly suppress the activity of MMP-1, MMP-2 or MMP-9, the decomposition of minimizing elastin laminin thereby can improve/slow down/prevent skin aging.
An object of the present invention is to provide a kind of purposes of Pulmonis Sus domestica extract, it is to be used to prepare the compositions that suppresses matrix metalloproteinase.
Only if definition in addition among this paper, otherwise the scientific and technical terminology that combines the present invention to use should have the implication of those skilled in the art's common sense.The implication of term and category should be clear and definite; Yet if there is any latent ambiguity, the definition that this paper provided has precedence over the definition of any dictionary or external source.Only and if context needs in addition,, singular references should comprise odd number otherwise should comprising plural number and plural term.
Term " Pulmonis Sus domestica extract " expression is with Pulmonis Sus domestica and perienchyma thereof the extract after extraction, and wherein this Pulmonis Sus domestica is not limited to fresh or refrigerated Pulmonis Sus domestica.In a preferred embodiment, Pulmonis Sus domestica extract extraction mode of the present invention is that (a) Pulmonis Sus domestica rubs the about 6.0-9.0 of back adding buffer adjustment pH value; (b) add ferment and in step (a), be incubated enzymolysis, heating up behind the enzymolysis makes the ferment inactivation; (c) after the adding acid solution is carried out Acid precipitation in step (b), filter and collect filtrating, and (d) add organic solvent in filtrating, the collecting precipitation thing obtains the Pulmonis Sus domestica extract.
In a preferred embodiments, this Pulmonis Sus domestica is to rub after removing the trachea part again.In a preferred embodiments, the pH value in the step of the present invention (a) is about 6.0-8.0,6.5-8.0,6.0-7.5 or about 7.0.In a preferred embodiments, employed buffer includes but not limited to sodium citrate or phosphoric acid salt in the step of the present invention (a).In a preferred embodiments, employed ferment includes but not limited to bromelain or protease M or its combination in the step of the present invention (b).In a preferred embodiments, employed acid solution is a strong acid in the step of the present invention (c), and it includes but not limited to hydrochloric acid, crosses chloric acid and trifluoracetic acid.In a preferred embodiments, employed organic solution includes but not limited to methanol, ethanol or isopropyl alcohol in the step of the present invention (d), and better is ethanol, and the best is a food stage ethanol.
In a preferred embodiment of the present invention, Pulmonis Sus domestica extract of the present invention can suppress the MMP activity, and described MMP is preferably MMP-1, MMP-2 or MMP-9.In another preferred embodiment, Pulmonis Sus domestica extract of the present invention can suppress the activity of MMP-1, MMP-2 and MMP-9 simultaneously.
In on the other hand, Pulmonis Sus domestica extract of the present invention can have improvement, slows down or prevent skin aging via the activity that suppresses MMP, particularly prevents the purposes of skin aging.
Term " prevents " expression prevention or stops symptom to produce, or improves or reply the symptom that has produced.
Term " skin aging " speech comprises that this kind aging sign includes but not limited to skin fragility; The forfeiture of collagen or elastin laminin; Oestrogen balance disappearance in the skin; Atrophoderma; The appearance of lines or wrinkle or the degree of depth comprise fine lines; Dyschromasia comprises black eye; Cutis laxa; Skin fatigue or pressure are for example because the skin due to ambient pressure such as pollution or the variations in temperature is outstanding; Xerosis cutis property; Skin scales off; Cell senescence; Skin tension, elasticity or glossy forfeiture; The forfeiture of skin fastness; The rough bark quality; Skin elasticity or elastic forfeiture.
To the interests and the improvement of skin beauty, can any following proof: the reduction of pore size; The improvement of skin tension, brilliance, the transparency or tension property; The promotion of antioxidant activity; The improvement of skin fastness, dilatancy, flexibility or pliability; Improvement on procollagen or the collagen production; The improvement on the skin quality or the promotion of redeformation; Improvement on reparation of skin barrier or the function: the apparent improvement of contoured skin; The reparation of skin gloss or brightness; Additional because of aging or necessary nutrient that cracked ends reduced or component in skin; The improvement that is communicated with in the Skin Cell; Increase in hyperplasia or the breeding; The skin cell metabolism that reduces because of aging or cracked ends is done the increase of using; The improvement that the skin moisturizing work is used; The promotion or the acceleration of cell conversion; The reinforcement of skin thickness; Increase on skin elasticity or the resilience; And the reinforcement that comes off.
In another preferred embodiments, Pulmonis Sus domestica extract of the present invention, compositions wherein comprises the required supporting agent of formation said composition in addition.
Term " supporting agent " or " acceptable supporting agent in the cosmetics " are meant diluent, excipient or analog, and it is known by each the sector person of ordinary skill in the field.
Compositions of the present invention also can further comprise the active component that can be used for preventing skin aging, and for example retinoic acid, retinol, Arbutin, hyaluronic acid, epidermal growth factor and other natural whiting become to grade.Compositions of the present invention can comprise in addition commonly uses cosmetic active agent, such as other commonly uses the Hypopigmentation agent, such as hydroquinone, ascorbic acid or Radix Glycyrrhizae quintessence liquid; Antiinflammatory; Anti-acne agent, such as salicylic acid; Exfoliant, such as 'alpha '-hydroxy acids, beta-hydroxy acid, ketone group acid, oxygen is sour or the oxygen diacid; Ascorbyl-phosphoryl-cholesterol; Sunscreen, but such as oxygen base benzophenone, methoxyl group cinnamic acid monooctyl ester, salicylic acid monooctyl ester, eight alkene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethise, di-2-ethylhexylphosphine oxide-BTA base tetramethyl butyl phenol (MBBT); Or age resister; Or its any combination.
In another preferred embodiment, compositions of the present invention comprises the Pulmonis Sus domestica extract of about 50 μ g/mL to the 500 μ g/mL of ultimate density.Preferably, compositions of the present invention comprises the Pulmonis Sus domestica extract of about 200 μ g/mL to 400 μ g/mL.The best is the Pulmonis Sus domestica extract that comprises about 300 μ g/mL.
Pulmonis Sus domestica extract of the present invention can institute the extraction solution original state use, or according to need concentrate, dilute, processings such as filtration and with activated carbon etc. decolour, deodorize handles the back use.In addition, will extract back solution and concentrate processing such as doing solid, spray drying, lyophilization, also can with the form use of dry thing.
Pulmonis Sus domestica extract of the present invention can be applicable in the pharmaceuticals of prevention, inhibition or doing well,improving to skin aging, accurate pharmaceuticals, cosmetics, feed additive or the food; And can use the former state of above-mentioned extract; Or in not damaging the extract scope, and the composition that uses in common pharmaceuticals, accurate pharmaceuticals, cosmetics or the food: excipient, tranquilizer, preservative agent, bonding agent, collapse components matching such as powder, hydro carbons, fatty acid, alcohols, esters, interfacial agent, metallic soaps, pH regulator agent, antiseptic, spice, wetting agent, powder body, UV absorbent, tackifier, pigment, antioxidant, whitening agent, chelating agen, oils or wax class and use.
The dosage form that Pulmonis Sus domestica extract of the present invention can appear for example has powder, pill, lozenge, injection, suppository, Emulsion, capsule, granule, liquor (comprising tincture, fluid tincture, spirits, suspension, limonada etc.), astringent, emulsifiable paste, emulsion, gel, spray, skin lotion, detergent, baths, substrate, buys powder, lipstick, ointment, warm and humid cloth, pasty state agent, plaster, quintessence oil, confection ingot or beverage etc.
Following examples should not be regarded as exceedingly limiting the present invention.Having common knowledge the knowledgeable in the technical field under the present invention can make amendment to the embodiment that this paper discussed under the situation that does not deviate from spirit of the present invention or category and change, and still belongs to scope of the present invention.
Instance
Instance 1 Pulmonis Sus domestica extract extraction mode
Freezing Pulmonis Sus domestica thaws and removes the trachea part after the back is cleaned with clear water, and 10 centimeters size bulks of cutting written treaty are earlier rubbed to there not being big massive texture with meat grinder; The extract (0.02M sodium citrate pH 7.0 ± 0.2) that adds 2 times of weight of Pulmonis Sus domestica with the abundant mix homogeneously of blender, weighs 5% (W/W) bromelain (2000GDU/g that rubs the dirty weight of Pulmonis Sus domestica; ST BIO) with the protease M ferment (5500untis/g of 0.1% (w/w); Amano), stir, in 50 ℃ of water-baths 3 hours with blender; After accomplishing, reaction let the ferment inactivation in 10 minutes with 90 ℃ of water-baths again; Be statically placed in and be cooled to 25 ℃ in the frozen water, the rest chamber relaxing the bowels with purgatives of warm nature was 1 hour after adding 1.5% (W/W) 6N hydrochloric acid stirred, and carried out the Acid precipitation reaction.Above-mentioned sample directly carries out board-like filtration with 1 μ m aperture cardboard, collects filtrate.With 95% ethanol (food stage) deposition of 3 times of volumes, put into 4 ℃ of cold-rooms 12 hours.With 8000 (* g), 30 minutes centrifugal collecting precipitates, precipitate dissolve for 7.0 times with 0.02M sodium citrate pH again.
MMP-1 is with merit ferment atlas analysis
1. cell culture and oxicity analysis
(1) cell culture:
To contain the a-MEM culture medium of 10%FBS, 1 * 104WS1 (BCRC 60300) cell of plantation cumulative volume 0.1mL is in 96 porose discs, and removal supernatant overnight is got the sample of concentration known; Culture medium to contain serum is mixed with 0,0.125, and 0.25; 0.5 5 of 1mg/mL analyze dosage, each 3 repetition.Filter with the filter membrane of 0.2 μ m again, get 0.1mL and add in the cell, remove supernatant after handling 24hr, again with serum-free but the a-MEM culture medium that contains 10ng/mL TNF-is mixed with 0; 0.125,0.25,0.5; 5 of 1mg/mL analyze each 3 repetition of dosage, with the filter membrane filtration of 0.2 μ m, get 0.1mL and add in the cell; Handle again after 24 hours and collect supernatant, be kept at-80 ℃, as follow-up MMP-1 with merit ferment atlas analysis sample.
(2) oxicity analysis:
The above-mentioned cell of still staying 96 porose discs, (100mL: mixed liquor 20mL), 37 ℃ were reacted 3 hours, in OD.490/630nm analysis of cells survival rate with MTS to add the culture medium contain serum.Get survival rate and be higher than the maximum concentration person of 80% (being defined as avirulence), analyze MMP-1 with merit ferment collection of illustrative plates.
2. with merit ferment atlas analysis
(1) preparation ferment running gel and electrophoretic analysis
Receive matter solution to contain 0.2% casein (casein), be mixed with the 10%SDS-PAGE running gel.Get sample dyestuff (sample dye) (the 200mM Tris-HCl of 4 μ L; PH value 6.8,8%SDS, 0.4% bromophenol blue; 40% glycerol) and even (the sample dyestuff: sample=1: 5) of the sample mix of 20 μ L; Placed room temperature 10 minutes, and injected (loading) and carry out electrophoretic analysis, finish to electrophoresis to fix 80 volts to the running gel of above-mentioned preparation.
(2) react with merit ferment collection of illustrative plates
Get the completion film and be immersed among the cleaning buffer solution I (Wash buffer I), under room temperature, rock washing 60 minutes.Change again to be immersed in and under room temperature, rock washing 40 minutes among the cleaning buffer solution II (Wash buffer II).In reaction buffer (Reaction buffer), 37 ℃ act on 20 hours at last.
(3) dye, move back and dye and strip analysis
The film that reaction is accomplished is positioned in the staining solution (0.15% Coomassie blue R250) and dyeed 60 minutes.Place again to dye in the solution (40% methanol, 10% acetic acid) and discolored about 30 minutes, rock to zona pellucida and occur.Be immersed at last in the RO water and shook 10 minutes.OD value with the quantitative transparent strip of Bio-Rad image processing system.
Can know the toxicity test chart of fibroblast by the Pulmonis Sus domestica extract shown in Figure 1A, even if Pulmonis Sus domestica extract concentration reaches 400 μ g/mL, can the pair cell toxigenicity and make cell death yet.Can know that by Figure 1B for matched group, Pulmonis Sus domestica extract concentration is high more, really can suppress MMP-1 more.Fig. 1 C then makes chart with the Pulmonis Sus domestica extract and the matched group of variable concentrations for the suppression ratio of MMP-1, shows that the Pulmonis Sus domestica extract of high concentration has the effect that suppresses MMP-1 more, and matched group does not then have identical inhibitory action.
MMP-2/-9 is with merit ferment atlas analysis
1. cell culture and oxicity analysis
(1) cell culture
To contain the DMEM culture medium of 10%FBS, 1 * 104NIH/3T3 (BCRC60008) cell of plantation cumulative volume 0.1mL is in 96 porose discs, and removal supernatant overnight is got the sample of concentration known; Culture medium to contain serum is mixed with 0,0.125, and 0.25,0.5; 5 of 1mg/mL analyze dosage, each 3 repetition, and the filter membrane with 0.2 μ m filters again, gets 0.1mL and adds in the cell; Remove supernatant after handling 24hr, again not contain serum but the DMEM culture medium that contains TNF-is mixed with 0,0.125,0.25; 0.5 5 of 1mg/mL analyze each 3 repetition of dosage, with the filter membrane filtration of 0.2 μ m, get 0.1mL and add in the cell; Handle again after 24 hours and collect supernatant, be kept at-80 ℃, as follow-up MMP-2/-9 with merit ferment atlas analysis sample.
(2) cytotoxicity analysis: with the cytotoxicity analysis test procedure of embodiment two.
2. with merit ferment atlas analysis
(1) preparation ferment running gel and electrophoretic analysis
Receive matter solution to be mixed with the 10%SDS-PAGE running gel to contain animal glue/casein.Get sample dyestuff (the 200mM Tris-HCl of 4 μ L; PH value 6.8,8%SDS, 0.4% bromophenol blue; 40% glycerol) and even (the sample dyestuff: sample=1: 5) of the sample mix of 20 μ L; Placed room temperature 10 minutes, the running gel that is injected into above-mentioned preparation carries out electrophoretic analysis, finishes to electrophoresis with fixing 80 volts.
(2) react with merit ferment collection of illustrative plates
Step is said with the merit ferment collection of illustrative plates reaction of embodiment two
(3) dye, move back and dye and strip analysis
Step with the dyeing of embodiment two, move back dye and strip analysis said.
Can know to the toxicity test chart of fibroblast that by the Pulmonis Sus domestica extract shown in Fig. 2 A Pulmonis Sus domestica extract concentration reaches 300 μ g/mL, can the pair cell toxigenicity and make cell death yet, confirm that Pulmonis Sus domestica extract pair cell is safe.Can know that by Fig. 2 B for matched group, Pulmonis Sus domestica extract concentration is high more, really can suppress MMP-2 and MMP-9 more.Fig. 2 C then makes chart with the Pulmonis Sus domestica extract and the matched group of variable concentrations for the suppression ratio of MMP-2, shows that the Pulmonis Sus domestica extract of high concentration has the effect that suppresses MMP-2 more, and matched group does not then have identical inhibitory action.Fig. 2 D then makes chart with the Pulmonis Sus domestica extract and the matched group of variable concentrations for the suppression ratio of MMP-9, shows that the Pulmonis Sus domestica extract of high concentration has the effect that suppresses MMP-9 more, and matched group does not then have identical inhibitory action.
Claims (16)
1. the purposes of a Pulmonis Sus domestica extract, it is to be used for preparation to suppress the active compositions of matrix metalloproteinase (MMP).
2. purposes according to claim 1, wherein said Pulmonis Sus domestica extract are to utilize following steps extractions and get:
(a) the about 6.0-9.0 of back adding buffer adjustment pH value is rubbed in Pulmonis Sus domestica and perienchyma thereof;
(b) add ferment and in step (a), be incubated enzymolysis, heating up behind the enzymolysis makes the ferment inactivation;
(c) after the adding acid solution is carried out Acid precipitation in step (b), filter and collect filtrating, and
(d) add organic solvent in filtrating, the collecting precipitation thing obtains the Pulmonis Sus domestica extract.
3. purposes according to claim 2, the Pulmonis Sus domestica of wherein said step (a) are fresh or freezing Pulmonis Sus domestica.
4. purposes according to claim 2, the pH value of wherein said step (a) is about 6.0-8.0,6.5-8.0,6.0-7.5 or about 7.0.
5. purposes according to claim 2, the buffer in the wherein said step (a) is sodium citrate or phosphoric acid salt.
6. purposes as claimed in claim 2, the ferment in the wherein said step (b) are bromelain or protease M or its combination.
7. purposes as claimed in claim 2, the insulation hydrolysis temperature in the wherein said step (b) are about 50 to 55 ℃.
8. purposes as claimed in claim 2, the intensification temperature in the wherein said step (b) are about 90 to 100 ℃.
9. purposes as claimed in claim 2, the acid solution in the wherein said step (c) are hydrochloric acid, mistake chloric acid or trifluoracetic acid.
10. purposes as claimed in claim 2, the organic solvent in the wherein said step (d) is methanol, ethanol or isopropyl alcohol.
11. purposes as claimed in claim 1, wherein said MMP is MMP-1, MMP-2 or MMP-9.
12. purposes as claimed in claim 1, wherein said Pulmonis Sus domestica extract is to suppress MMP-1, MMP-2 and MMP-9 simultaneously.
13. purposes as claimed in claim 1, skin aging can be improved, slows down or prevented to the active compositions of wherein said inhibition matrix metalloproteinase (MMP).
14. comprising in addition, purposes as claimed in claim 1, wherein said compositions constitute the required supporting agent of said composition.
15. purposes as claimed in claim 1, the content of wherein said extract in said compositions are about 50 μ g/mL to 500 μ g/mL.
16. purposes as claimed in claim 1, wherein said compositions can be cosmetics, skin care products, food, health food, health food, animal-use drug article, feed additive or the mankind and use medicine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW099137522A TWI399209B (en) | 2010-11-01 | 2010-11-01 | Use of porcine lung extract as metrix metalloproteinase inhibitor |
| TW099137522 | 2010-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102462699A true CN102462699A (en) | 2012-05-23 |
| CN102462699B CN102462699B (en) | 2013-05-08 |
Family
ID=46067007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101892182A Expired - Fee Related CN102462699B (en) | 2010-11-01 | 2011-06-30 | Use of porcine lung extract as matrix metalloproteinase inhibitor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102462699B (en) |
| TW (1) | TWI399209B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108441494A (en) * | 2018-03-13 | 2018-08-24 | 华南农业大学 | The application that E2 is generated in promoting gonad granulocyte of sow MMP2 genes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238182A (en) * | 1998-06-05 | 1999-12-15 | 何德惠 | Process for extracting coarse lipo-hepinette from lung of animal |
| WO2005009498A2 (en) * | 2003-07-17 | 2005-02-03 | Boston Scientific Limited | Decellularized bone marrow extracellular matrix |
| CN1579421A (en) * | 2003-08-05 | 2005-02-16 | 上海复旦复华药业有限公司 | Freeze-dried powder of pig's lung surface matter, its preparation method and use |
| US20060211026A1 (en) * | 2005-03-17 | 2006-09-21 | Roche Palo Alto Llc | Methods for assessing emphysema |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040138103A1 (en) * | 2002-11-07 | 2004-07-15 | Procyte Corporation | Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto |
-
2010
- 2010-11-01 TW TW099137522A patent/TWI399209B/en not_active IP Right Cessation
-
2011
- 2011-06-30 CN CN2011101892182A patent/CN102462699B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238182A (en) * | 1998-06-05 | 1999-12-15 | 何德惠 | Process for extracting coarse lipo-hepinette from lung of animal |
| WO2005009498A2 (en) * | 2003-07-17 | 2005-02-03 | Boston Scientific Limited | Decellularized bone marrow extracellular matrix |
| CN1579421A (en) * | 2003-08-05 | 2005-02-16 | 上海复旦复华药业有限公司 | Freeze-dried powder of pig's lung surface matter, its preparation method and use |
| US20060211026A1 (en) * | 2005-03-17 | 2006-09-21 | Roche Palo Alto Llc | Methods for assessing emphysema |
Non-Patent Citations (1)
| Title |
|---|
| Y. GUSHIMA, ETC.: "Expression of matrix metalloproteinases in pigs with", 《EUROPEAN RESPIRATORY JOURNAL》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108441494A (en) * | 2018-03-13 | 2018-08-24 | 华南农业大学 | The application that E2 is generated in promoting gonad granulocyte of sow MMP2 genes |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201219044A (en) | 2012-05-16 |
| TWI399209B (en) | 2013-06-21 |
| CN102462699B (en) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5011121B2 (en) | Composition for promoting collagen and / or hyaluronic acid production | |
| JP2022191378A (en) | Yeast based mask for improving health of skin, hair and scalp | |
| CN103037886A (en) | Cosmetic uses of modified stressed yeast extracts and related compositions | |
| US20100189709A1 (en) | Elastase inhibitor | |
| JP6158471B2 (en) | Skin aging inhibitor | |
| KR20130048164A (en) | Jellyfish collagen peptide mixture | |
| JP7466246B1 (en) | Wrinkle improving agent and its manufacturing method | |
| CN102821751A (en) | Human dermal epithelial cell growth promoter, and skin composition for external use and cosmetic material including the same | |
| JP2012087091A (en) | Cosmetic | |
| CN102462699B (en) | Use of porcine lung extract as matrix metalloproteinase inhibitor | |
| CN112469819B (en) | Cosmetic composition and method for preparing neural stem cell conditioned medium | |
| JP4753922B2 (en) | Raw materials for cosmetics | |
| JP2002284632A (en) | Extinction substance for superoxide anion extracted from sake lees as effective component | |
| JP2005001995A (en) | Cosmetic | |
| JP2003171307A (en) | Matrix metalloprotease inhibitor | |
| JP2007039394A (en) | External preparation for skin for preventing and ameliorating aging | |
| JP2006273822A (en) | Cosmetic containing clear liquor (shochu) lees | |
| KR20140072419A (en) | Anti-Wrinkle Composition | |
| CN105982825A (en) | Use of composition in production of cosmetics with moisturizing function | |
| JP6486745B2 (en) | Whitening composition | |
| KR20200038755A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Fermented Vibumum Opulus | |
| JP6944606B1 (en) | Manufacturing method of cosmetic composition | |
| JP6951710B2 (en) | Mushroom culture composition | |
| JP6619530B2 (en) | Composition for inhibiting matrix metalloprotease production | |
| KR20010035745A (en) | a protease which degrades keratin layers of skin surface, a microorganism which produces the protease and a cosmetic composition containing a culture solution thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130508 Termination date: 20190630 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |